Health

ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City

ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City

Geneva, Switzerland and Boston, MA – April 16, 2018– ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman‘s reproductive health and pregnancy, today announced that the company will host a key opinion leader (KOL) meeting focused on in vitro fertilization (IVF) Thursday, April 26 from […]

Veritas Pharma Enters Into Share Purchase Agreement with 3 Carbon Extractions Inc.

Veritas Pharma Enters Into Share Purchase Agreement with 3 Carbon Extractions Inc.

3 Carbon is in the business of designing cannabis extraction facilities and utilizing its own proprietary extraction methods. VANCOUVER, British Columbia, April 16, 2018 (GLOBE NEWSWIRE) — Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:) (“Veritas” or the “Company”) is pleased to announce that it has entered into a Share Purchase Agreement (“Purchase Agreement”) with 3 Carbon Extractions Inc. (“3 Carbon”) to […]

Herantis Pharma tiedottaa positiivisista väliaikatuloksista Lymfactin-tutkimuksessa sekundäärisen lymfaturvotuksen hoidossa

Herantis Pharma tiedottaa positiivisista väliaikatuloksista Lymfactin-tutkimuksessa sekundäärisen lymfaturvotuksen hoidossa Herantis Pharma Oyj Yhtiötiedote 16.4. 2018 kello 9:00 Herantis Pharma Oyj (“Herantis”) tiedotti tänään positiivisista tuloksista käynnissä olevan kliinisen Lymfactin-tutkimuksen turvallisuusarvioinnista. Kyseinen Vaiheen 1 kliininen tutkimus selvittää Lymfactin-geeniterapiavalmisteen turvallisuutta ja siedettävyyttä sekundäärisen lymfaturvotuksen hoidossa. Tutkimukseen on rekrytoitu kaikkiaan 15 potilasta, joista kertyneen aineiston perusteella turvallisuutta arvioiva riippumaton asiantuntijakomitea (Data Monitoring Committee, […]

Herantis Pharma announces positive interim data from Lymfactin study in secondary lymphedema

Herantis Pharma announces positive interim data from Lymfactin study in secondary lymphedema Herantis Pharma Plc Company release 16 Apr 2018 at 9:00 am Herantis Pharma Plc (“Herantis”) announced today positive results from a safety evaluation in the ongoing Phase 1 clinical study assessing the safety and tolerability of the company‘s investigational gene therapy product Lymfactin® in the treatment of secondary […]

Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy

Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy   Lugano, Switzerland, and Tokyo, Japan, April 16, 2018 – Taiho Pharmaceutical Co., Ltd., a Japanese R&D-driven specialty pharma focused on oncology and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, […]